Literature DB >> 16236885

Delays in the diagnosis and treatment of lung cancer.

Eija-Riitta Salomaa1, Susanna Sällinen, Heikki Hiekkanen, Kari Liippo.   

Abstract

STUDY
OBJECTIVES: This study was undertaken to measure delays of diagnosis and to assess the causes for those delays in patients with lung cancer. In addition, the relation of delay times and survival was analyzed.
DESIGN: A retrospective study based on patient records. Dates for symptoms, visits to doctors, investigations, treatment, and death were recorded.
SETTING: Patients who were found to have lung cancer at Turku University Hospital, Finland, during 2001. PATIENTS: Records of 132 patients were reexamined.
RESULTS: The median delay in patient presentation from first symptoms to first appointment with a general practitioner (GP) was 14 days. The median delay by the GP before writing a referral was 16 days, the median referral delay was 8 days, the median delay from the first visit to a specialist until the diagnosis was 15 days, and the median treatment delay was also 15 days. Thirty percent of patients received treatment within 1 month from the first hospital visit, and 61% received treatment within 2 months. The median symptom-to-treatment delay was almost 4 months. The delay in seeing a specialist was shorter in patients with advanced cancer and small cell lung cancer. About half of our patients fulfilled the criteria of the British Thoracic Society recommendations. A longer specialist treatment delay seemed to correlate with better survival in advanced disease, but it was not an independent significant factor for survival.
CONCLUSIONS: Several reasons for long delays were found, but on many occasions patients underwent numerous consecutive procedures before a diagnosis of cancer was confirmed. Shortening the diagnostic and treatment delay times might be possible with little extra cost by a multidisciplinary team approach and by rapid access to carefully planned investigations, but decreasing the patient delay might be more difficult. This study shows that long specialist treatment delays are not correlated with worse prognosis in patients with advanced disease. In patients with more limited disease, the delay time may be more critical, and if curative treatment is the goal, the diagnostic process should proceed without needless delay to avoid a situation in which curable disease becomes incurable.

Entities:  

Mesh:

Year:  2005        PMID: 16236885     DOI: 10.1378/chest.128.4.2282

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  79 in total

1.  Characteristics and predictors of missed opportunities in lung cancer diagnosis: an electronic health record-based study.

Authors:  Hardeep Singh; Kamal Hirani; Himabindu Kadiyala; Olga Rudomiotov; Traber Davis; Myrna M Khan; Terry L Wahls
Journal:  J Clin Oncol       Date:  2010-06-07       Impact factor: 44.544

2.  Effect of delays on survival in patients with lung cancer.

Authors:  Francisco Javier González-Barcala; José María García-Prim; José Manuel Alvarez-Dobaño; Milagros Moldes-Rodríguez; María Teresa García-Sanz; Antonio Pose-Reino; Luis Valdés-Cuadrado
Journal:  Clin Transl Oncol       Date:  2010-12       Impact factor: 3.405

3.  Implementing effective and sustainable multidisciplinary clinical thoracic oncology programs.

Authors:  Raymond U Osarogiagbon; Richard K Freeman; Mark J Krasna
Journal:  Transl Lung Cancer Res       Date:  2015-08

4.  Pathologic Upstaging in Patients Undergoing Resection for Stage I Non-Small Cell Lung Cancer: Are There Modifiable Predictors?

Authors:  Matthew J Bott; Aalok P Patel; Traves D Crabtree; Graham A Colditz; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Stephen Broderick; Bryan F Meyers; Varun Puri
Journal:  Ann Thorac Surg       Date:  2015-08-13       Impact factor: 4.330

5.  An exploration of urban and rural differences in lung cancer survival among medicare beneficiaries.

Authors:  Lisa R Shugarman; Melony E S Sorbero; Haijun Tian; Arvind K Jain; J Scott Ashwood
Journal:  Am J Public Health       Date:  2007-10-30       Impact factor: 9.308

Review 6.  Measuring improvement in populations: implementing and evaluating successful change in lung cancer care.

Authors:  Xinhua Yu; Lisa M Klesges; Mathew P Smeltzer; Raymond U Osarogiagbon
Journal:  Transl Lung Cancer Res       Date:  2015-08

7.  'One-stop shop': lung cancer patients' and caregivers' perceptions of multidisciplinary care in a community healthcare setting.

Authors:  Satish K Kedia; Kenneth D Ward; Siri A Digney; Bianca M Jackson; April L Nellum; Laura McHugh; Kristina S Roark; Orion T Osborne; Fayre J Crossley; Nicholas Faris; Raymond U Osarogiagbon
Journal:  Transl Lung Cancer Res       Date:  2015-08

Review 8.  Integration of tobacco cessation services into multidisciplinary lung cancer care: rationale, state of the art, and future directions.

Authors:  Graham W Warren; Kenneth D Ward
Journal:  Transl Lung Cancer Res       Date:  2015-08

9.  Time to treatment in patients with stage III non-small cell lung cancer.

Authors:  Li Wang; Candace R Correa; James A Hayman; Lujun Zhao; Kemp Cease; Dean Brenner; Doug Arenberg; Jeffery Curtis; Gregory P Kalemkerian; Feng-Ming Kong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-02-21       Impact factor: 7.038

10.  Timeliness of care and prognosis in patients with lung cancer.

Authors:  F J Gonzalez-Barcala; J A Falagan; J M Garcia-Prim; L Valdes; J M Carreira; A Puga; P Martín-Lancharro; M T Garcia-Sanz; D Anton-Sanmartin; J C Canive-Gomez; A Pose-Reino; R Lopez-Lopez
Journal:  Ir J Med Sci       Date:  2013-10-04       Impact factor: 1.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.